vs

Side-by-side financial comparison of BK Technologies Corp (BKTI) and STANDARD BIOTOOLS INC. (LAB). Click either name above to swap in a different company.

BK Technologies Corp is the larger business by last-quarter revenue ($21.5M vs $19.6M, roughly 1.1× STANDARD BIOTOOLS INC.). BK Technologies Corp runs the higher net margin — 19.7% vs -177.4%, a 197.1% gap on every dollar of revenue. On growth, BK Technologies Corp posted the faster year-over-year revenue change (20.0% vs -11.5%). BK Technologies Corp produced more free cash flow last quarter ($2.8M vs $-23.1M). Over the past eight quarters, STANDARD BIOTOOLS INC.'s revenue compounded faster (-12.2% CAGR vs -21.6%).

BK Technologies Corp designs, manufactures and sells analog and digital two-way radio communications equipment and related accessories. It serves public safety departments, first responders, government agencies and commercial clients primarily across North America, focusing on reliable, mission-critical communication solutions.

Standard BioTools Inc., previously known as Fluidigm Corp., is an American life science tools company that offers analytical mass cytometry systems for flow cytometry and tissue imaging, along with associated assays and reagents, as well as an automated genomic analysis instrument and a variety of microfluidic arrays, or integrated fluidic circuits (IFCs), and consumables with fully kitted reagents. Custom assays and services are available with all systems and applications.

BKTI vs LAB — Head-to-Head

Bigger by revenue
BKTI
BKTI
1.1× larger
BKTI
$21.5M
$19.6M
LAB
Growing faster (revenue YoY)
BKTI
BKTI
+31.4% gap
BKTI
20.0%
-11.5%
LAB
Higher net margin
BKTI
BKTI
197.1% more per $
BKTI
19.7%
-177.4%
LAB
More free cash flow
BKTI
BKTI
$25.9M more FCF
BKTI
$2.8M
$-23.1M
LAB
Faster 2-yr revenue CAGR
LAB
LAB
Annualised
LAB
-12.2%
-21.6%
BKTI

Income Statement — Q4 FY2025 vs Q3 FY2025

Metric
BKTI
BKTI
LAB
LAB
Revenue
$21.5M
$19.6M
Net Profit
$4.2M
$-34.7M
Gross Margin
50.5%
48.5%
Operating Margin
19.7%
-168.5%
Net Margin
19.7%
-177.4%
Revenue YoY
20.0%
-11.5%
Net Profit YoY
15.6%
-28.8%
EPS (diluted)
$1.06
$-0.09

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
BKTI
BKTI
LAB
LAB
Q4 25
$21.5M
Q3 25
$24.4M
$19.6M
Q2 25
$21.2M
$21.8M
Q1 25
$19.1M
$40.8M
Q4 24
$17.9M
Q3 24
$20.2M
$22.1M
Q2 24
$20.3M
$22.5M
Q1 24
$45.5M
Net Profit
BKTI
BKTI
LAB
LAB
Q4 25
$4.2M
Q3 25
$3.4M
$-34.7M
Q2 25
$3.7M
$-33.5M
Q1 25
$2.1M
$-26.0M
Q4 24
$3.7M
Q3 24
$2.4M
$-26.9M
Q2 24
$1.7M
$-45.7M
Q1 24
$-32.2M
Gross Margin
BKTI
BKTI
LAB
LAB
Q4 25
50.5%
Q3 25
49.9%
48.5%
Q2 25
47.4%
48.8%
Q1 25
47.0%
48.4%
Q4 24
41.2%
Q3 24
38.8%
54.9%
Q2 24
37.3%
46.1%
Q1 24
53.1%
Operating Margin
BKTI
BKTI
LAB
LAB
Q4 25
19.7%
Q3 25
19.8%
-168.5%
Q2 25
18.9%
-118.1%
Q1 25
15.3%
-80.8%
Q4 24
12.3%
Q3 24
12.9%
-120.9%
Q2 24
10.0%
-134.5%
Q1 24
-132.2%
Net Margin
BKTI
BKTI
LAB
LAB
Q4 25
19.7%
Q3 25
14.1%
-177.4%
Q2 25
17.7%
-153.7%
Q1 25
11.2%
-63.8%
Q4 24
20.4%
Q3 24
11.7%
-122.0%
Q2 24
8.2%
-203.3%
Q1 24
-70.6%
EPS (diluted)
BKTI
BKTI
LAB
LAB
Q4 25
$1.06
Q3 25
$0.87
$-0.09
Q2 25
$0.96
$-0.09
Q1 25
$0.55
$-0.07
Q4 24
$0.96
Q3 24
$0.63
$-0.07
Q2 24
$0.47
$-0.12
Q1 24
$-0.27

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
BKTI
BKTI
LAB
LAB
Cash + ST InvestmentsLiquidity on hand
$22.8M
$129.4M
Total DebtLower is stronger
Stockholders' EquityBook value
$44.7M
$399.7M
Total Assets
$63.8M
$539.6M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
BKTI
BKTI
LAB
LAB
Q4 25
$22.8M
Q3 25
$21.5M
$129.4M
Q2 25
$11.9M
$158.6M
Q1 25
$8.9M
$150.9M
Q4 24
$7.1M
Q3 24
$4.2M
$210.6M
Q2 24
$3.0M
$269.8M
Q1 24
$287.1M
Total Debt
BKTI
BKTI
LAB
LAB
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
Q3 24
$55.2M
Q2 24
$55.1M
Q1 24
$55.0M
Stockholders' Equity
BKTI
BKTI
LAB
LAB
Q4 25
$44.7M
Q3 25
$41.0M
$399.7M
Q2 25
$36.8M
$424.5M
Q1 25
$32.4M
$454.6M
Q4 24
$29.8M
Q3 24
$26.0M
$489.3M
Q2 24
$23.4M
$510.3M
Q1 24
$577.3M
Total Assets
BKTI
BKTI
LAB
LAB
Q4 25
$63.8M
Q3 25
$66.9M
$539.6M
Q2 25
$60.4M
$557.0M
Q1 25
$56.1M
$579.6M
Q4 24
$51.5M
Q3 24
$46.4M
$681.5M
Q2 24
$48.9M
$708.7M
Q1 24
$777.7M
Debt / Equity
BKTI
BKTI
LAB
LAB
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
Q3 24
0.11×
Q2 24
0.11×
Q1 24
0.10×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
BKTI
BKTI
LAB
LAB
Operating Cash FlowLast quarter
$3.0M
$-22.2M
Free Cash FlowOCF − Capex
$2.8M
$-23.1M
FCF MarginFCF / Revenue
13.2%
-118.1%
Capex IntensityCapex / Revenue
0.7%
4.5%
Cash ConversionOCF / Net Profit
0.71×
TTM Free Cash FlowTrailing 4 quarters
$18.4M
$-111.1M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
BKTI
BKTI
LAB
LAB
Q4 25
$3.0M
Q3 25
$10.4M
$-22.2M
Q2 25
$3.9M
$-20.7M
Q1 25
$2.1M
$-30.3M
Q4 24
$3.8M
Q3 24
$5.7M
$-27.9M
Q2 24
$4.1M
$-39.0M
Q1 24
$-62.5M
Free Cash Flow
BKTI
BKTI
LAB
LAB
Q4 25
$2.8M
Q3 25
$10.1M
$-23.1M
Q2 25
$3.7M
$-22.6M
Q1 25
$1.8M
$-35.3M
Q4 24
$3.4M
Q3 24
$5.2M
$-30.1M
Q2 24
$3.9M
$-41.0M
Q1 24
$-63.3M
FCF Margin
BKTI
BKTI
LAB
LAB
Q4 25
13.2%
Q3 25
41.3%
-118.1%
Q2 25
17.3%
-103.6%
Q1 25
9.6%
-86.6%
Q4 24
19.2%
Q3 24
25.8%
-136.4%
Q2 24
19.2%
-182.2%
Q1 24
-138.9%
Capex Intensity
BKTI
BKTI
LAB
LAB
Q4 25
0.7%
Q3 25
1.5%
4.5%
Q2 25
1.2%
8.7%
Q1 25
1.4%
12.4%
Q4 24
2.0%
Q3 24
2.2%
10.2%
Q2 24
1.0%
8.6%
Q1 24
1.7%
Cash Conversion
BKTI
BKTI
LAB
LAB
Q4 25
0.71×
Q3 25
3.04×
Q2 25
1.04×
Q1 25
0.98×
Q4 24
1.04×
Q3 24
2.40×
Q2 24
2.46×
Q1 24

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

BKTI
BKTI

Segment breakdown not available.

LAB
LAB

Consumables$8.7M45%
Services And Other Revenue$5.8M29%
Instruments$5.1M26%

Related Comparisons